- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
- Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- POS0646 EFFECT OF OLOKIZUMAB ON THE NEUTROPHIL-LYMPOCYTE RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Poster View
Rheumatoid arthritis
POS0646 EFFECT OF OLOKIZUMAB ON THE NEUTROPHIL-LYMPOCYTE RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract
Background: The neutrophil-lymphocyte ratio (NLR) is a biomarker of residual inflammation and is an independent predictor of MACE and thrombosis events.2 Its changes correlate with changes in the levels of CRP, serum amyloid, fibrinogen, haptoglobin, and lipoprotein(a).1 IL-1 inhibitors, IL-6 receptor inhibitors and TNF inhibitors can reduce NLR.2-4 It was recently shown that direct blockade of IL-6 also reduced this biomarker in high CV risk patients.1 However, there are no similar investigations for olokizumab (OKZ), which directly binds to IL-6.
Objectives: To investigate the effect of OKZ in doses of 64mg every two weeks (q2w) or every 4 weeks (q4w) on NLR in patients with RA previously enrolled in the CREDO program. To determine correlations between NLR changes and RA activity indicators changes.
Methods: Post hoc analysis phase 3 studies (NCT02760368, NCT02760407, NCT02760433).
Neutrophil-lymphocyte ratio was calculated by dividing the absolute number of neutrophils (ANC) by absolute number of lymphocytes (ALC) in the venous blood (NLR=ANC/ALC). Baseline parameters and their changes were analyzed in four groups: OKZ q2w, OKZ q4w, adalimumab group (ADA) and placebo group (PBO) all at background of MTX. A Wilcoxon signed-rank test was used to evaluate the statistical significance between baseline parameters and after 12 and 24 weeks of therapy. Pearson correlation analysis was used to determine the relationship between NLR, ANC, ALC changes and the main indices of RA activity. A p-value <0.050 was considered statistically significant.
Results: NLR, ANK, ALC were studied in 4 groups of patients: OKZ q2w (n=745), OKZ q4w (n=777), ADA (n=462), PBO (n=454). The baseline levels of ANC and ALC were comparable in all four groups. NLR baseline level in the appropriate groups Me[Q1,Q3]: 3.12[2.24; 4.44], 3.21[2.33; 4.37], 3.21[2.35; 4.48], 3.21[2.44; 4.77]. NLR decrease had been recorded in all active therapy groups, respectively 34.3%, 33.0%, 32.0% (vs BL p < 0.001) after 12 weeks of therapy. NLR decrease was minimal in the placebo group (2.8%, vs BL p>0.05). After 24 weeks of therapy, the NLR decrease had been 33.0%, 29.6%, 31.8% in the active therapy groups (vs BL p<0.001), 6.5% in the placebo group (p<0.001). The NLR reduction occurred due to ANC decrease, with unchanged ALC in the OKZ groups. In ADA group ANC decreased less, but ALC increased (Figure 1). Correlation analysis revealed a positive weak relationship between changes in DAS28, CRP, ESR and ΔANC, ΔNLR, and a negative correlation with ΔALC. CDAI changes were not associated with changes of hematological parameters (Table 1).
- Download figure
- Open in new tab
- Download powerpoint
Figure 1.
View this table:
- View inline
- View popup
Table 1.
Pearson Coefficient Correlation. Change from Baseline at Week 12
Conclusion: Post hoc analysis of CREDO 1-3 showed an association of direct IL-6 blockade by olokizumab and NLR decrease, which was connected with the neutrophil component reduction. NLR changes correlated with changes in RA activity indices and laboratory parameters.
REFERENCES: [1] Adamstein NH, Cornel JH, Davidson M, et al. JAMA Cardiol. 2023;8(2):177-181. doi:10.1001/jamacardio.2022.4277
[2] Adamstein NH, MacFadyen JG, Rose LM, et al. Eur Heart J. 2021;42(9):896-903. doi:10.1093/eurheartj/ehaa1034
[3] Broch K, Anstensrud AK, Woxholt S, et al. J Am Coll Cardiol. 2021;77(15):1845-1855. doi:10.1016/j.jacc.2021.02.049
[4] Sen R, Kim E, Napier RJ, et al. Arthritis Rheumatol. 2023;75(2):232-241. doi:10.1002/art.42333
Acknowledgements: NIL.
Disclosure of Interests: Eugen Feist Abbvie, BMS, Galapagos, Lilly, Novartis, Medac, Pfizer, R-Pharm, Alina Egorova R-Pharm, Evgeny Alekseev JSC “R-Pham.”
- Atherosclerosis
- biological DMARD
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Atherosclerosis
- biological DMARD
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens